4569.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:45):

Stats
आज की मात्रा	84 900.00
औसत मात्रा	69 440.00
बाजार मूल्य	105.02B
EPS	¥0 ( 2024-02-05 )
अगली कमाई की तारीख	( ¥0 ) 2024-05-08
Last Dividend	¥32.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	24.63
ATR14	¥1.224 (0.07%)

मात्रा सहसंबंध

लंबा: 0.12 (neutral)

छोटा: 0.91 (very strong)

Signal:(59.072) Expect same movement, but be aware

KYORIN Holdings, Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

KYORIN Holdings, Inc. सहसंबंध - मुद्रा/वस्त्र

0.74
( moderate )

0.86
( strong )

-0.19
( neutral )

0.86
( strong )

-0.20
( neutral )

-0.87
( strong negative )

KYORIN Holdings, Inc. वित्तीय

Annual	2022
राजस्व:	¥113.27B
सकल लाभ:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
राजस्व:	¥113.27B
सकल लाभ:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
राजस्व:	¥105.53B
सकल लाभ:	¥49.44B (46.85 %)
EPS:	¥68.62

FY	2021
राजस्व:	¥102.90B
सकल लाभ:	¥51.63B (50.17 %)
EPS:	¥106.99

Financial Reports:

No articles found.

KYORIN Holdings, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥32.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

KYORIN Holdings, Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.14%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥10.00	2006-09-26
Last Dividend	¥32.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	¥862.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.6	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.48	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.60

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8563.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
7893.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7037.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
6368.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5269.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4343.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
3501.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
2735.T	Ex Dividend Junior	2023-08-30	Annually	0.00%
9628.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8163.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0356	1.500	9.29	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0238	1.200	9.21	10.00	[0 - 0.3]
returnOnEquityTTM	0.0339	1.500	-0.735	-1.102	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.53	0.800	2.34	1.871	[1 - 3]
quickRatioTTM	1.327	0.800	6.90	5.52	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.116	-1.500	8.06	-10.00	[0 - 0.6]
interestCoverageTTM	75.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.164	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.429	1.000	6.18	6.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.0408	1.000	-1.185	-1.185	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.405	1.000	8.86	8.86	[0.2 - 2]
assetTurnoverTTM	0.670	0.800	8.87	7.10	[0.5 - 2]
Total Score				10.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.65	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.0339	2.50	-0.472	-1.102	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.226	1.500	5.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0702	1.000	-0.745	0	[0.1 - 0.5]
Total Score				4.34

KYORIN Holdings, Inc.

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.